<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of refractory <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) is a common clinical challenge </plain></SENT>
<SENT sid="1" pm="."><plain>In either <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> refractory UC, the disease may continue to remain active, even though the patient is on appropriate therapy </plain></SENT>
<SENT sid="2" pm="."><plain>It is important to reassess and characterize the patient's disease before adding new medications to the current medical regimen </plain></SENT>
<SENT sid="3" pm="."><plain>After determining the current extent and severity of the UC-ruling out other causes of <z:hpo ids='HP_0002573'>bloody diarrhea</z:hpo> and determining what complications are present-new treatment approaches can then be started </plain></SENT>
<SENT sid="4" pm="."><plain>It is critical to first optimize oral <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) therapy combined with rectal <z:chebi fb="0" ids="6775">5-ASA</z:chebi> or <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> suppositories, plus <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> or <z:chebi fb="0" ids="6775">5-ASA</z:chebi> enemas or foam preparations </plain></SENT>
<SENT sid="5" pm="."><plain>Oral or intravenous <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> are appropriate to use if needed, but alternative approaches must be used for long-term maintenance </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="1" ids="50667">6-Mercaptopurine</z:chebi> (<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi>) or <z:chebi fb="2" ids="2948">azathioprine</z:chebi> can be very helpful for severe <z:hpo ids='HP_0011010'>chronic</z:hpo> refractory UC </plain></SENT>
<SENT sid="7" pm="."><plain>In those patients who do not respond to <z:chebi fb="0" ids="6775">5-ASA</z:chebi> medications, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, and <z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> or <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, infliximab offers an important approach for induction and maintenance of remission for refractory <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> as well as for select cases of refractory <z:hpo ids='HP_0011009'>acute</z:hpo> UC </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> use is an alternative medical approach for the refractory <z:hpo ids='HP_0011009'>acute</z:hpo> UC patient </plain></SENT>
<SENT sid="9" pm="."><plain>Colectomy with ileal pouch-anal anastomosis remains a valuable option for the refractory <z:hpo ids='HP_0011010'>chronic</z:hpo> or <z:hpo ids='HP_0011009'>acute</z:hpo> UC patient, because it can provide both a "cure" for the disease, as well as eliminate ineffective medications with their associated side effects </plain></SENT>
</text></document>